68Ga-FAPI-46 PET/CT与18F-FDG PET/CT在不明肝脏病变中的前瞻性头对头比较
该前瞻性研究纳入59例疑似肝内病变患者,比较68Ga-FAPI-46 PET/CT与18F-FDG PET/CT对不明肝脏病变的定性能力。结果显示FAPI-46视觉分析敏感度100%、特异度94%,FDG敏感度70%、特异度88%,FAPI-46敏感度显著更高(P<0.001),且检出更多肝外原发肿瘤(10 vs 3)。结论认为FAPI-46 PET/CT优于FDG PET/CT。
要点
- FAPI-46 PET/CT对不明肝脏病变的视觉分析敏感度100%、特异度94%,高于FDG的70%和88%。
- FAPI-46检出10个肝外原发肿瘤,FDG仅检出3个。
- 90.9%良性肝病变在两种PET上均无明显摄取。
核心结论
- 68Ga-FAPI-46 PET/CT在不明肝脏病变定性方面优于18F-FDG PET/CT。
研究设计与样本
- 前瞻性纳入59例疑似肝内病变患者,以病理、影像学或随访为参考标准,并与PET扫描进行关联评估。
- 对16例肝细胞癌/胆管癌、肝外恶性肿瘤肝内转移或良性病变患者的样本进行成纤维细胞活化蛋白免疫组化评估。
主要发现
- 视觉分析显示44例患者FAPI-46摄取增高(敏感度100%、特异度94%),32例患者FDG avid病变(敏感度70%、特异度88%),FAPI-46敏感度显著更高(P<0.001)。
- FAPI-46 PET/CT检出10个肝外原发肿瘤,FDG PET/CT检出3个。
- 原发肝胆肿瘤的SUVmax、最大肿瘤/本底比值和平均肿瘤/本底比值在FAPI-46 PET/CT上均显著高于FDG PET/CT(均P<0.05)。
关键数值与推荐
- FAPI-46视觉分析敏感度100%、特异度94%;FDG敏感度70%、特异度88%。
- 原发肝胆肿瘤SUVmax、最大和平均肿瘤/本底比值在FAPI-46上均显著高于FDG(均P<0.05)。
临床怎么用
- 对不明肝脏病变,可优先考虑68Ga-FAPI-46 PET/CT以提高病变定性和肝外原发肿瘤检出。
- 良性肝病变在FAPI-46上多无明显摄取,有助于鉴别。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This study aimed to compare the performance of 68Ga-labeled fibroblast activation protein inhibitor 46 ([68Ga]Ga-FAPI-46) PET/CT and [18F]FDG PET/CT in characterizing unclear hepatic lesions. Methods: We prospectively evaluated 59 patients with suspected intrahepatic lesions. Tumor radiologic features, pathology, or follow-up examinations were assessed as reference methods in correlation with PET scans. On [68Ga]Ga-FAPI-46 PET/CT, additional abdominal dynamic imaging was performed. We measured the SUV and calculated tumor-to-liver background ratios for both scans. Fibroblast activation protein expression was assessed by immunohistochemistry in samples obtained from 16 patients with hepatocellular carcinoma/cholangiocarcinoma, intrahepatic metastases (IMs) from extrahepatic malignancies, or benign lesions. Results: Primary hepatobiliary tumors (PHBTs), including 76 hepatocellular carcinomas in 22 patients, 24 cholangiocarcinomas in 5 patients, 136 IMs in 16 patients, and 55 benign lesions in 16 patients, were determined by histology (n = 162) and radiologic examinations (n = 129). On the basis of visual analysis, 44 patients showed elevated [68Ga]Ga-FAPI-46 uptake (sensitivity, 100%; specificity, 94%), whereas 32 patients showed [18F]FDG-avid lesions (sensitivity, 70%; specificity, 88%). Sensitivity was significantly higher in [68Ga]Ga-FAPI-46 PET/CT than in [18F]FDG PET/CT (P < 0.001). Fifty (90.9%) benign liver lesions in 14 patients (87.5%) showed negligible uptake on both PET scans, and 1 (1.8%) benign liver lesion in 1 patient showed increased [18F]FDG uptake alone. [68Ga]Ga-FAPI-46 PET/CT revealed 10 extrahepatic primary tumors, versus 3 in [18F]FDG PET/CT. SUVmax for PHBTs, maximum tumor-to-background ratio for PHBTs, and mean tumor-to-background ratio for PHBTs were significantly higher on [68Ga]Ga-FAPI-46 PET/CT than on [18F]FDG PET/CT (all P < 0.05). Conclusion: [68Ga]Ga-FAPI-46 PET/CT is superior to [18F]FDG PET/CT in characterizing unclear hepatic lesions.
引用
- Stanzel S, Nazerani-Zemann T, Weitzer F, et al. Prospective Head-to-Head Comparison of Fibroblast Imaging with [68Ga]Ga-FAPI-46 PET/CT and [18F]FDG PET/CT in Unclear Hepatic Lesions. J Nucl Med. 2026. PMID: 41991336. doi:10.2967/jnumed.125.271597
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。